

# Effect of haloperidol on behavioral sensitization and cognition in methylphenidate and bupirone-methylphenidate co-administered rats

Nausheen Alam<sup>1</sup> and Rahila Ikram<sup>2</sup>

<sup>1</sup>Federal Urdu University of Arts, Science and Technology, Karachi, Pakistan

<sup>2</sup>Department of Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan

**Abstract:** Attenuation of methylphenidate-induced behavioral sensitization and cognitive tolerance by bupirone co-administration has been reported previously. Dopamine D<sub>2</sub>-receptors are considered to be important in methylphenidate-induced sensitization. This study was designed to monitor the responsiveness of D<sub>2</sub> receptors following long-term methylphenidate, bupirone and their co-administration in rats by the challenge dose of haloperidol. Effects of haloperidol challenge dose (1 mg/kg i.p.) were monitored after 6 weeks (till the behavioral sensitization produced) from oral repeated (twice a day for 6 week) administration of methylphenidate (2mg/kg/day), bupirone (10mg/kg/day) and their co-administration. Motor activity was compared by using familiar environment of home cage and novel environment of open field and cognitive activity was compared by using water maze were monitored 30, 60, and 90 minutes post injection respectively. We found that haloperidol reduced motor activity in familiar as well as in novel environment and showed impaired cognitive performance in water maze. The effects were more pronounced in methylphenidate treated rats as compared to bupirone and methylphenidate co-administration treated rats. Increased response of haloperidol in methylphenidate treated rats can be explained in terms of super-sensitization of D<sub>2</sub> receptors, which results in behavioral sensitization that is not observed in co-administration treated rats. Bupirone prevents D<sub>2</sub> receptor's super-sensitization by increasing serotonergic inhibitory influence on dopamine neuron.

**Keywords:** Methylphenidate, Bupirone, cognition, sensitization, D<sub>2</sub> receptors, Haloperidol.

## INTRODUCTION

Central nervous system stimulants are the drugs that produce euphoria, increase intellect, cognition, performance and delay onset of fatigue. Despite these beneficial effects, most central nervous system stimulants are of little therapeutic value because long-term use of these drugs produces tolerance on cognitive behavior, reverse tolerance on motor activity and dependence (Leith and Kuczenski., 1982). These drugs are, therefore, classified as the drugs of abuse (Robinson and Berridge, 2008).

Methylphenidate, a drug of choice in attention deficit hyperactivity (ADHD), causes amplification of dopamine (DA) release in the central nervous system that contributes to the attention enhancing aspect of the drug (Volkow *et al.*, 2002). It blocks noradrenalin and DA transporter protein (Barrett *et al.*, 2005) and enhances extra-cellular concentrations of catecholamine. Therapeutic doses of methylphenidate that improve cognition in rats increases norepinephrine and DA efflux in Prefrontal cortex (PFC) relative to limbic structures (Berridge *et al.*, 2006). DA reuptake in PFC is through both the norepinephrine transporter and the DA transporter (Sesack *et al.*, 1998; Yamamoto and Novotney, 1998). It is likely that the sensitization-inducing effects and therapeutic efficacy of

methylphenidate are connected to modification in DA and norepinephrine transmission in PFC. The brain dopaminergic system and the involvement of DA D<sub>2</sub>-receptors are considered to be important in methylphenidate-induced sensitization (Millan *et al.*, 1998). Sensitization to amphetamine and methamphetamine was reported to be prevented by D<sub>2</sub> antagonist (Meng *et al.*, 1998; White *et al.*, 1998).

Drugs of abuse after long term administration enhance the effectiveness of 5-HT<sub>1A</sub> somatodendritic receptors. Cognitive tolerance and motor sensitization can be modulated by the central serotonergic system (Hall *et al.*, 2004; Muller *et al.*, 2003). Repeated bupirone administration attenuates psychostimulant-induced behavioral sensitization and cognitive tolerance (Alam *et al.*, 2015; Alam *et al.*, 2016).

Haloperidol, a dopamine D<sub>2</sub> receptor antagonist, known to block the effect of amphetamine on motor cortex (Feeney and Hovda, 1983) and reduce motor function in rats (Feeney *et al.*, 1982). Haloperidol, when injected into the rat nucleus accumbens, disturbs acquisition antagonism that may affect cognitive outcome. Studies show that Morris water maze acquisition in normal rats is disturbed after chronic haloperidol treatment (Terry *et al.*, 2002).

The present study is designed to monitor the responsiveness of D<sub>2</sub> receptors by the challenge dose of haloperidol, following long-term oral administration of methylphenidate, bupirone and their co-administration

\*Corresponding author: e-mail: nausheenasarosh6@hotmail.com

and to investigate whether co-administration of bupirone increases the usefulness and reduces the side effects of methylphenidate.

## **MATERIALS AND METHODS**

### ***Animals***

Forty eight rats were caged in pairs, in a quiet room, under a 12 hr. cycle of light/dark and room temperature was controlled at 24±2°C. Cubes of standard rodent diet with free tap water access was given so that rats could become familiar to the environment. They were acclimatized to various handling procedures in order to nullify stress effects. All the performed experiments were according to the approved protocols and were in accordance with the rules and regulations given by local animal care committee.

### ***Drugs***

Methylphenidate HCl purchased from Sigma was dissolved in saline NaCl 0.9% and bupirone (Research Biochemicals Incorporated) was prepared in distilled water. The drugs were administered by oral route twice a day individually and also co-administered to the 3<sup>rd</sup> group. Methylphenidate at the dose of 2mg/kg/day (Aoyama *et al.*, 1990), bupirone at the dose of 10mg/kg/day (Naito *et al.*, 2003) and co-administered methylphenidate at the dose of 2mg/kg/day and bupirone at the dose of 10mg/kg/day according to the weight of the rats whereas, the control rats were treated with (0.9%) saline per oral twice a day. Haloperidol available in 5 mg/ml ampoules manufactured under license from G.D. Searle and Co. U.S.A, by Searle Pakistan Ltd. Laboratories was used in the present study.

### ***Experimental design***

The protocol of experiment was designed to administer methylphenidate and saline to 1<sup>st</sup> group of treated rats, bupirone and saline to 2<sup>nd</sup> group of treated rats, methylphenidate and bupirone to 3<sup>rd</sup> group of treated rats and saline to control rats orally two times daily (8.00 AM and 8.00 PM) for six weeks till the sensitization is produced. Among the three groups of treated rats, the 1<sup>st</sup> group was given methylphenidate in the dose of 2mg/kg/day, the 2<sup>nd</sup> group was given bupirone at the dose of 10mg/kg/day and 3<sup>rd</sup> group was given methylphenidate at the dose of 2mg/kg/day and bupirone at the dose of 10mg/kg/day according to the weight of the rats. Controlled rats were given saline 2.0ml/kg/day according to the weight of the rats. After six weeks challenge, the dose of Haloperidol 1mg/kg i.p. was given to all the treated and controlled rats to monitor the drug effects on the behavioral parameters 30 minutes post injection.

### ***Behavioral studies***

To avoid the order effect all the treatments were carried out in a balance design. The behavioral parameters monitored during treatment are as follows.

### ***Home cage activity (familiar environment)***

To monitor activity of rats in familiar environment, home cages were used. Cages were (26x26x26 cm) transparent Perspex with sawdust cover floor. In these cages, the rats were placed individually for 15 min before monitoring the activity to make them familiar with the environment. The numbers of cage-crossings after 15 minutes were counted for 10 minutes (Batool *et al.*, 2000). The activity of methylphenidate, bupirone, co-administration and saline treated rats in the familiar environment were monitored 30 minutes post haloperidol injection. The activities of the controlled and the test animals were monitored in a balanced design to avoid order effect.

### ***Open field activity (novel environment)***

The novel environment of open field consists of a square area (76x76 cm) with 42 cm high walls and the apparatus floor was divided by lines into 25 squares all of the equal size. The experiment was performed under the white light in a quiet room. The animal taken out from the cage was placed in the open field at the center square. The numbers of squares crossed were counted for 5 minutes (Ikram *et al.*, 2007). Activity of the drug treated groups and the controlled rats, were monitored 60 minutes post haloperidol injection. To avoid the order effect, the open field activity of the rats was scored in a balanced design.

### ***Water Maze test***

In the present study, the Water Maze apparatus used, consisted of a (60x30cms) transparent glass tank, rectangular in shape, filled with room temperature-water opacified with powdered milk, to the depth of 12cm. A wooden platform (15x13cms) was placed at a fixed location, hidden 2cm below the surface of the water. The effects on the spatial memory were examined by assessing performance in Water Maze (WM) test. Initially and during the training sessions, the rats were trained, every rat was placed into the tank of water facing the wall and allowed 2 min to climb and locate onto the submerged platform. Within the time allowed, if the rat failed to find the platform, it was guided gently onto the platform. After the acquisition phase, retention latency was recorded to test the memory function of the rats. The retention latency is the time taken by each rat to locate the hidden platform after the training. The cognitive test of the drug treated and the controlled animals were monitored 90 minutes post haloperidol injection. The experiment was performed in a balanced design to avoid the time and the order effect.

## **STATISTICAL ANALYSIS**


The results are represented as mean ±S.D. The statistical analysis was performed by using the SPSS software (version 16.0). The data on the effects of haloperidol on the drug treated and the controlled animals in home cage, open field and water maze were performed using three-

way ANOVA analysis of variance. Newman-Keul test was performed for Post hoc comparison of the groups. The level of significance was considered significant if the values lied between  $p < 0.05$  and  $p < 0.01$ .

## RESULTS

### *Effect of Haloperidol on motor activity in familiar environment in Methylphenidate treated, Buspirone treated and co-administration of Methylphenidate-Buspirone treated rats.*

The data on home cage analyzed by three-way ANOVA showed significant effects of methylphenidate ( $F=112.2$ ,  $df=1,24$ ,  $p < 0.01$ ), buspirone ( $F=57.4$ ,  $df=1,24$ ,  $p < 0.01$ ) haloperidol ( $F=241$ ,  $df=1,24$ ,  $p < 0.01$ ) and significant interactions between haloperidol\*buspirone ( $F=36.9$ ,  $df=1,24$ ,  $p < 0.01$ ), haloperidol\*methylphenidate ( $F=74.9$ ,  $df=1,24$ ,  $p < 0.01$ ), buspirone\*methylphenidate ( $F=116.8$ ,  $df=1,24$ ,  $p < 0.01$ ) and haloperidol\*buspirone\*methylphenidate ( $F=107.7$ ,  $df=1,24$ ,  $p < 0.01$ ).




The effect of haloperidol 1mg/kg I.P. on familiar environment (home cage) in methylphenidate treated, buspirone treated and co-administration of methylphenidate-buspirone treated rats. The values are means  $\pm$ SD ( $n=6$ ). The significant differences by Newman-Keuls test: \* $p < 0.01$  from similarly treated saline injected rats. \*\* $p < 0.01$ , + $p < 0.05$  from similarly injected saline treated rats. # $p < 0.01$  from similarly injected methylphenidate treated rats following three-way ANOVA.

**Fig. 1:** Effect of haloperidol in methylphenidate, buspirone and their co-administration treated rats on familiar environment.

Post hoc Newman-Keuls test demonstrated that the activity of methylphenidate treated saline injected rats was greater ( $p < 0.01$ ) in a familiar environment than saline treated saline injected rats. Haloperidol decreased the cage crossing in methylphenidate, buspirone and methylphenidate-buspirone co-administered rats significantly ( $p < 0.01$ ) compared to the similarly treated saline injected rats and significantly ( $p < 0.05$ ) from the similarly injected saline treated rats. Buspirone significantly decreased ( $p < 0.01$ ) the cage crossings in co-administration treated and saline injected rats but revealed

no effect on haloperidol injected rats than similarly injected methylphenidate treated rats.



The effect of Haloperidol 1mg/kg I.P. on square crossing of novel environment (open field) in methylphenidate treated, buspirone treated and co-administration of methylphenidate-buspirone treated rats. The values are means  $\pm$ SD ( $n=6$ ). The significant differences by Newman-Keuls test: \* $p < 0.05$ , \*\* $p < 0.01$  from similarly treated saline injected rats. + $p < 0.05$ , \*\* $p < 0.01$  from similarly injected saline treated rats. # $p < 0.01$  from similarly injected methylphenidate treated rats following three-way ANOVA.

**Fig. 2:** Effect of haloperidol in methylphenidate, buspirone and their co-administration treated rats on novel environment.


### *Effect of Haloperidol on motor activity in novel environment in Methylphenidate treated, Buspirone treated and co-administration of Methylphenidate-Buspirone treated rats.*

The data analyzed by three-way ANOVA showed significant effects of methylphenidate ( $F=39.4$ ,  $df=1,24$ ,  $p < 0.01$ ), haloperidol ( $F=160.8$ ,  $df=1,24$ ,  $p < 0.01$ ) and non-significant effects of buspirone ( $F=3.8$ ,  $df=1,24$ ,  $p > 0.05$ ). The interactions between haloperidol\*buspirone ( $F=6.2$ ,  $df=1,24$ ,  $p < 0.05$ ), haloperidol \*methylphenidate ( $F=14.2$ ,  $df=1,24$ ,  $p < 0.01$ ), buspirone \*methylphenidate ( $F=5.9$ ,  $df=1,24$ ,  $p < 0.05$ ) and haloperidol\*buspirone\*methylphenidate ( $F=17.7$ ,  $df=1,24$ ,  $p < 0.01$ ) are significant.

Post hoc Newman-Keuls test demonstrated that haloperidol significantly ( $p < 0.01$ ) decreased square crossed activity in methylphenidate, buspirone and co-administration treated rats and ( $p < 0.05$ ) in saline treated rats from similarly treated saline injected rats. Square crossed activity increased significantly ( $p < 0.01$ ) in saline injected methylphenidate treated and significantly increased ( $p < 0.05$ ) in saline injected co-administration treated rats from the similarly injected saline treated rats whereas significantly decreased ( $p < 0.01$ ) in saline injected co-administration treated rats from similarly injected methylphenidate treated rats.

**Effect of Haloperidol on memory in Methylphenidate treated, Buspirone treated and co-administration of Methylphenidate-Buspirone treated rats**

The data analyzed by three-way ANOVA showed significant effects of methylphenidate ( $F=12.22$ ,  $df=1,24$ ,  $p<0.01$ ), haloperidol ( $F=63.26$ ,  $df=1,24$ ,  $p<0.01$ ) and non-significant effect of buspirone ( $F=0.12$ ,  $df=1,24$ ,  $p>0.05$ ). The interactions between haloperidol\*buspirone ( $F=0.22$ ,  $df=1, 24$ ,  $p>0.05$ ), haloperidol \*methylphenidate ( $F=0.47$ ,  $df=1,24$ ,  $p>0.05$ ), haloperidol\*buspirone \*methylphenidate ( $F=3.99$ ,  $df=1,24$ ,  $p>0.05$ ) are non-significant and the significant interaction between buspirone \*methylphenidate ( $F=18.15$ ,  $df=1,24$ ,  $p<0.01$ ).



The effect of Haloperidol 1m/kg I.P. on Water Maze in methylphenidate treated, buspirone treated and co-administration of methylphenidate-buspirone treated rats. The values are means  $\pm$ SD (n=6). The significant differences by Newman-Keuls test: \* $p<0.01$  from similarly treated saline injected rats. + $p<0.01$  from similarly injected saline treated rats. # $p<0.01$  from similarly injected methylphenidate treated rats. ! $p<0.01$  from similarly injected buspirone treated rats following three-way ANOVA.

**Fig. 3:** Effect of haloperidol in methylphenidate, buspirone and their co-administration treated rats on memory

Post hoc analysis by Newman-Keuls test demonstrated that haloperidol significantly decreased ( $p<0.01$ ) memory in saline, methylphenidate, buspirone and co-administration of methylphenidate-buspirone treated rats from saline injected similarly treated rats. Memory significantly ( $p<0.01$ ) enhanced in saline injected co-administration treated rats but significantly decreased ( $p<0.01$ ) in saline and haloperidol injected buspirone treated and haloperidol injected methylphenidate treated rats from the similarly injected saline treated rats. Significant memory ( $p<0.01$ ) improvement occur in saline and haloperidol injected co-administration treated rats from similarly injected buspirone treated rats and in haloperidol injected co-administration treated rats from similarly injected methylphenidate treated rats.

**DISCUSSION**

It has been reported previously that buspirone can attenuate methylphenidate-induced behavioral

sensitization and cognitive tolerance (Alam *et al.*, 2015; Alam *et al.*, 2016). In the present study, the responsiveness of D<sub>2</sub> receptors were studied following long-term methylphenidate, buspirone and their co-administration in rats by the haloperidol challenge dose. Haloperidol belongs to the class of neuroleptics that blocks postsynaptic D<sub>2</sub> receptors, affect motor and cognitive functions in rats (Terry *et al.*, 2002; Feeney *et al.*, 1982). Challenge dose of haloperidol reduced motor activity in familiar environment of home cage and novel environment of open field (figs. 1 and 2). The activity of rats in all treated and control groups were greater in open field as compare to the home cage, which could be explained in terms of anxiogenic effect of novel environment of open field. Indeed other authors also have reported anxiety and increase locomotor activity by using various paradigms (Bina *et al.*, 2014). The decrease in motor activity (fig. 1 & 2) and cognitive performance (fig. 3) were greater in all the drug treated groups of rats in comparison to controlled rats but among similarly treated groups, the effect of haloperidol was significantly higher in methylphenidate treated rats as compared to the buspirone treated and co-administration treated groups. Various studies documented that haloperidol has been used to assess the sensitized behavioral responses produced by the administration of psychostimulants (Costa *et al.*, 2004; Hatzipetros *et al.*, 2007)

Stimulants are supposed to be harmless ways for enhancing energy and concentration levels, increasing school performance or using for recreation and reducing the desire and duration of sleep (Habibzadeh *et al.*, 2011). Youths show an increasing predilection for the consumption of prescription stimulants (Johnston *et al.*, 2007). Previous studies have demonstrated that the repeated methylphenidate administration can cause behavioral sensitization and cognitive tolerance (Alam and Najam, 2013; Alam and Najam, 2014; Juárez and Vázquez-Cortés, 2010). The cognitive effects of methylphenidate can be task dependent on the brain function (Alam and Najam, 2014; Volkow and Swanson, 2008; Clatworthy *et al.*, 2009). For example, methylphenidate administration leads to decrease activation during decision making (Schlösser *et al.*, 2009) and reversal learning (Dodds *et al.*, 2008) tasks, but during reaction time tasks, there is an increased activation (Müller *et al.*, 2005).

The brain dopaminergic system and the involvement of DA D<sub>2</sub>-receptors are considered to be important in methylphenidate-induced sensitization and cognitive tolerance (Millan *et al.*, 1998). DA modulates cognitive performance in part via its regulation of the prefrontal cortex through DA D<sub>1</sub> and D<sub>2</sub> receptors (Goldman-Rakic, 1998). Methylphenidate increases DA signaling in the brain and is used in the treatment of ADHD and other neuropsychiatric disorders to enhance attention and

cognition (Ackerman and White, 1992; Clatworthy *et al.*, 2009). Sensitization to amphetamine and methamphetamine was reported to be prevented by D<sub>2</sub> antagonist (Meng *et al.*, 1998; White *et al.*, 1998). Psychostimulant-induced behavioral sensitization (Juárez and Vázquez-Cortés, 2010) is directly related with subsensitization of DA D<sub>2</sub> auto receptor (Bevan, 1983) and supersensitization of DA postsynaptic receptors (Ackerman and White, 1992, Hopf *et al.*, 2007). In the present study methylphenidate increase locomotor activity monitored in familiar and novel environments, whereas methylphenidate and co-administration of methylphenidate and buspirone produce cognitive enhancement monitored in Water Maze, however challenge dose of haloperidol reduce motor activity and impaired cognitive performance. Acute haloperidol administration produces the behavioral suppressant effects by blocking postsynaptic D<sub>2</sub> receptors (Klemm, 1993). Haloperidol is known to block the effect of amphetamine produced on motor cortex (Feeney and Hovda, 1983) and slowed motor function in rats (Feeney *et al.*, 1982). Morris Water Maze acquisition also shown to disturbed after haloperidol treatment in normal rats (Terry *et al.*, 2002). The effect of haloperidol on locomotor activity and cognitive performance were greater in methylphenidate treated rats compared to saline and co-administration treated rats. In the regulation of behavior central serotonergic system also play an important role along with dopaminergic system (Oades, 2008). Serotonin has inhibitory influence on the activity of DA neurotransmitter (Haleem, 2006). Therefore psychostimulant-induced behavioral sensitization could be modulated by serotonergic system (Hall *et al.*, 2004; Muller *et al.*, 2003).

Psychostimulant induced sensitization increases 5HT, hyperactivates 5HT<sub>1A</sub> receptors, which in addition to DA is a core mechanism of action for the drug addiction. 5HT<sub>1A</sub> receptors mainly facilitate psychostimulant addiction related behavior (Muller *et al.*, 2007). Drugs of abuse after long term administration enhance the effectiveness of 5-HT<sub>1A</sub> somatodendritic receptors. Repeated Buspirone administration, decreased somatodendritic 5-HT<sub>1A</sub> receptor responsiveness (Haleem *et al.*, 2007). Somatodendritic 5-HT<sub>1A</sub> receptors desensitization by buspirone co-administration will increase the serotonergic inhibitory influence on the effect of DA neurons (Khan and Haleem, 2006) to reduce cognitive tolerance and locomotor sensitization produced by psycho-stimulants. It has been observed that there is significant reduced motor activity and cognitive performance in all treated groups but effect was more pronounced in methylphenidate treated rats after haloperidol challenge dose. From this it can be suggested that observed effect may be due to increased D<sub>2</sub> receptor sensitivity following long-term methylphenidate administration leads to behavioral sensitization and

cognitive tolerance that could be prevented by buspirone co-administration.

## CONCLUSION

In conclusion the increased response of haloperidol in methylphenidate treated rats can be explained in terms of super-sensitization of D<sub>2</sub> receptors that is not observed in co-administration treated rats. It is suggested that co-administration of methylphenidate and buspirone prevents D<sub>2</sub> receptors super-sensitization by increasing serotonergic inhibitory influence on the DA neurons and facilitate the use of methylphenidate in different cognitive disorders.

## REFERENCES

- Ackerman JM and White FJ (1992). Decreased activity of rat A10 Dopamine neurons following withdrawal from repeated cocaine. *Eur. J. Pharmacol.*, 218: 171-173.
- Alam N and Najam R (2013). Dose related neurochemical and behavioral effects of  $\alpha$ -Methylphenidate in rats. *International Journal of Scientific & Engineering Research*, 4(7): 407.
- Alam N and Najam R (2014). Cognition-enhancing effect of oral therapeutic doses of Methylphenidate in rats. *Medical Forum Monthly*, 25(1): 36-39.
- Alam N, Najam R and Khan SS (2015). Attenuation of Methylphenidate-induced tolerance on cognition by Buspirone co-administration. *Pak. J. Pharm. Sci.*, 28(5): 1601-1605.
- Alam N, Najam R and Naeem S (2016). Attenuation of Methylphenidate-induced sensitization by Buspirone co-administration. *Pak. J. Pharm. Sci.*, 29(2): 585-590.
- Aoyama T, Kotaki H and Iga T (1990). Dose-dependent kinetics of methylphenidate enantiomers after oral administration of racemic Methylphenidate to rats. *J. Pharmacobiol. Dyn.*, 13: 647-652.
- Barrett SP, Darredeau C, Bordy LE and Pihl RO (2005). Characteristics of Methylphenidate misuse in a university student sample. *Can. J. Psychiatry*, 50: 457-461.
- Batool F, Saify ZS, Haleem MA and Haleem DJ (2000) Neurochemical and extra pyramidal effects of atypical neuroleptic clozapine in rats. *Pak. J. Pharm. Sci.* 13(1): 47-55.
- Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE and Schmeichel B *et al.* (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. *Biol. Psychiatry*, 60: 1111-20.
- Bevan P (1983). Repeated apomorphine treatment causes behavioral super sensitivity and dopamine D<sub>2</sub> receptor hyposensitivity. *Neurosci. Lett.*, 35(2): 185-189.
- Bina P, Rezvanfard M, Ahmadi S and Zarrindast MR (2014). Anxiolytic-Like Effects and Increase in

- Locomotor Activity Induced by Infusions of NMDA into the Ventral Hippocampus in Rat: Interaction with GABAergic System. *Basic Clin. Neurosci.*, **5**(4): 267-276.
- Cao Ah, YuL, Wang YW, Wang JM, Yang LJ and Lei GF (2012). Effects of methylphenidate on attentional set-shifting in a genetic model of attention-deficit/hyperactivity disorder. *Behav. Brain Funct.*, pp.8-10.
- Clatworthy P, Lewis S, Brichard L, Hong Y, Izquierdo D, Clark L, Cools R, Aigbirhio F, Baron J, Fryer T and Robbins T (2009) Dopamine release in dissociable striatal subregions predicts the different effects of oral Methylphenidate on reversal learning and spatial working memory. *J. Neurosci.*, **29**: 4690-4696
- Dodds C, Müller U, Clark L, van Loon A, Cools R and Robbins T (2008). Methylphenidate has differential effects on blood oxygenation level-dependent signal related to cognitive sub processes of reversal learning. *J. Neurosci.*, **28**: 5976-5982.
- Feeney DM and Hovda DA (1983). Amphetamine and apomorphine restore tactile placing after motor cortex injury in the cat. *Psychopharmacology* (Berl.), **79**: 67-71
- Feeney DM, Gonzalez A and Law WA (1982) Amphetamine, Haloperidol and experience interact to affect rate of recovery after motor cortex injury. *Science*, **217**: 855-857.
- Goldman-Rakic P (1998). The cortical Dopamine system: role in memory and cognition. *Adv. Pharmacol.*, **42**: 707-711.
- Habibzadeh A, Alizadeh M, Malek A, Maghbooli L, Shoja MM and Ghabili K (2011). Illicit Methylphenidate use among Iranian medical students: prevalence and knowledge. *Drug Des. Devel. Ther.*, **5**: 71-76.
- Haleem DJ (2006). Serotonergic modulation of dopamine neurotransmission: A mechanism for enhancing therapeutics in schizophrenia. *J. Coll. Physicians Surg. Pak.*, **16**(8): 556-562.
- Haleem DJ, Samad N and Haleem MA (2007). Reversal of Haloperidol-induced extra-pyramidal symptoms by Buspirone: a time-related study. *Bahvioural Pharmacology*, **18**(2): 147-153.
- Hall FS, Sora I, Drgonova J, Li XF, Goeb M and Uhl GR (2004). Molecular mechanisms underlying the rewarding effects of cocaine. *Ann. NY. Acad. Sci.*, **1025**: 47-56.
- Hatzipetros T, Raudensky JG, Soghomonian JJ and Yamamoto BK (2007). Haloperidol Treatment after High-Dose Methamphetamine Administration Is Excitotoxic to GABA Cells in the Substantia Nigra Pars Reticulata. *J. Neurosci.*, **27**(22): 5895-5902
- Hopf FW, Martin M, Chen BT, Bowers MS, Mohamedi MM and Bonci A (2007). Withdrawal from intermittent ethanol exposure increases probability of burst firing in VTA neurons *in vitro*. *J. Neurophysiol.*, **98**: 2297-2310.
- Ikram H, Samad N and Haleem DJ (2007). Neurochemical and behavioral effects of m-CPP in a rat model of *Tardive dyskinesia*. *Pak. J. Pharm Sci.*, **20**(3): 188-195.
- Johnston LD, O'Malley PM, Bachman JG and Schulenberg JE (2007). Monitoring the Future National Survey Results on Drug use, 1975-2006: Volume II, College Students and Adults Ages. pp.19-45.
- Juárez J and Vazquez-Cortes C (2010). Corticosterone treatment before puberty sensitizes the effect of oral Methylphenidate on locomotor activity in preadolescence and produces differential effects in adulthood. *Brain Research*, **30**(1346): 195-203.
- Khan A and Haleem DJ (2006) 5-HT-1A receptor responsiveness following subchronic administration of Buspirone. *Pak. J. Pharm. Sci.*, **19**(4): 333-337.
- Klemm WR (1993). The catalepsy of blocked Dopaminergic receptors. *Psychopharmacology* (Berl.) ; **111**(2): 251-255.
- Leith NJ and Kuczenski R (1982). Two dissociable components of behavioral sensitization following repeated amphetamine administration. *Psychopharmacology* (Berl.) **76**: 310-315.
- Meng Z, Feldpaush DL and Merchant KM (1998). Clozapine and Haloperidol block the induction of behavioral sensitization to amphetamine and associated genomic responses in rats. *Brain Res. Mol. Brain Res.*, **61**: 39-50.
- Millan MJ, Newman Tancredi A, Brocco M, Gobert A, Lejeune F, Audinot V, Rivet JM, Schreiber R, Dekeyne A, Spedding M, Nicolas JP and Peglion JL (1998). S 18126 (2-[4-(2,3-dihydrobenzo[1,4] dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl), a potent, selective and competitive antagonist at Dopamine D4 receptors: An *in vitro* and *in vivo* comparison with L 745,870 (3-(4-[4-chlorophenyl] piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. *J. Pharmacol. Exp. Ther.*, **287**: 167-186.
- Müller CP and Huston JP (2007). Dopamine activity in the occipital and temporal cortices of rats: Dissociating effects of sensory but not pharmacological stimulation. *Synapse*, **61**: 254-258.
- Muller CP, Carey RJ and Huston JP (2003). Serotonin as an important mediator of cocaine's behavioral effects. *Drugs Today*, **39**: 497-511.
- Muller U, Suckling J, Zelaya F, Honey G, Faessel H, Williams S, Routledge C, Brown J, Robbins T and Bullmore E (2005). Plasma level-dependent effects of Methylphenidate on task-related functional magnetic resonance imaging signal changes. *Psychopharmacology* (Berl); **180**: 624-633.
- Naito H, Nakamura A, Inoue M and Suzuki Y (2003) Effect of anxiolytic drugs on air-puff-elicited ultrasonic vocalization in adult rats. *Exp. Anim.*, **52**: 409-414.

- Oades RD (2008). Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD) *Progress in Brain Research*, **172**: 543-565.
- Robinson TE and Berridge KC (2008). Review. The incentive sensitization theory of addiction: Some current issues. *Philos Trans R. Soc. Lond. B Biol. Sci.*, **363**: 3137-3146.
- Schlösser R, Nenadic I, Wagner G, Zysset S, Koch K and Sauer H (2009). Dopaminergic modulation of brain systems subserving decision making under uncertainty: A study with fMRI and Methylphenidate challenge. *Synapse.*, **63**: 429-442.
- Sesack SR, Hawrylak VA, Melchitzky DS and Lewis DA (1998). Dopamine innervation of a subclass of local circuit neurons in monkey prefrontal cortex: ultrastructural analysis of tyrosine hydroxylase and parvalbuminimmunoreactive structures. *Cereb Cortex.*, **8**: 614-622.
- Terry AV Jr, Hill WD, Parikh V, Evans DR, Waller JL and Mahalik SP (2002) Differential effects of chronic Haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. *Psychopharmacology (Berl)*; **164**: 360-368.
- Volkow N and Swanson J (2008). The action of enhancers can lead to addiction. *Nature.*, 451:520.
- Volkow ND, Wang GJ, Fowler JS, Logan J, Jayne M and Franceschi D *et al.* (2002). Nonhedonic food motivation in humans involves Dopamine in the dorsal striatum and Methylphenidate amplifies this effect. *Synapse.*, **44**: 175-180.
- White FJ, Joshi A, Koeltzow TE and Hu XT (1998). Dopamine receptor antagonists fail to prevent induction of cocaine sensitization. *Neuropsychopharmacology*, **18**: 26-40.
- Yamamoto BK and Novotney S (1998). Regulation of extra cellular Dopamine by the norepinephrine transporter. *J. Neurochem.*, **71**: 2